Last reviewed · How we verify
Senl-T7
At a glance
| Generic name | Senl-T7 |
|---|---|
| Sponsor | Hebei Senlang Biotechnology Inc., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study of SenL-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (NA)
- Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBL (NA)
- Senl-T7 CAR-T Cells for Treatment of Relapsed or Refractory CD7+ Lymphoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Senl-T7 CI brief — competitive landscape report
- Senl-T7 updates RSS · CI watch RSS
- Hebei Senlang Biotechnology Inc., Ltd. portfolio CI